Grifols | GenomeWeb

Grifols

Hologic CEO Steve MacMillan said that the deal is so compelling that the firm needed to do it now.

Through their arrangement, Singulex has granted Grifols an exclusive license to its single-molecule counting technology for use in blood donor and plasma screening.

The firm's blood screening revenues received a boost from services performed for the Japanese Red Cross Society by its partner, Grifols. 

NEW YORK (GenomeWeb) — Hologic reported after the close of the market on Wednesday a 6 percent increase in revenues for its fiscal fourth quarter, including a 2 percent uptick in revenues for its Diagnostics business.

NEW YORK (GenomeWeb) – Grifols today announced the Procleix HEV assay for detection of hepatitis E has received CE marking.

NEW YORK (GenomeWeb) – Grifols has garnered a CE-IVD mark for ID Core XT, a bead array-based assay for molecular blood group typing, the company said this week.

NEW YORK (GenomeWeb News) — Grifols said today that it has been selected by the Japanese Red Cross Society as a partner in nucleic acid screening of the country's 5.3 million annual blood donations.

Spanish genetic testing firm Progenika Biopharma will continue to pursue its business objectives after Barcelona-based plasma products manufacturer Grifols acquired a 60 percent stake in the firm for for €37 million ($48.4 million), according to its CEO.

NEW YORK (GenomeWeb News) – Barcelona-based plasma products manufacturer Grifols has acquired a 60 percent stake in Progenika Biopharma for €37 million ($48.4 million), the firms announced earlier this week.

The deal will take Novartis into the blood genotyping market.

Pages

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.